Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enzon Pharmaceuticals Inc (ENZN)

Enzon Pharmaceuticals Inc (ENZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enzon Pharmaceuticals Inc 20 Commerce Drive Suite 135 Cranford NJ 07016 USA

www.enzon.com P: 732-980-4500

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.

Key Statistics

Overview:

Market Capitalization, $K 5,047
Enterprise Value, $K 667
Shares Outstanding, K 74,215
Float, K 73,918
% Float 99.60%
Short Interest, K 0
Short Float 0.00%
Days to Cover 1.00
Short Volume Ratio 0.36
% of Insider Shareholders 0.40%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 30 K
Annual Net Income, $ 780 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -820 K
EBIT, $ -4,160 K
EBITDA, $ -4,160 K

Growth:

1-Year Return -59.72%
3-Year Return -74.34%
5-Year Return -90.35%
5-Year Revenue Growth -85.71%
5-Year Earnings Growth 50.00%
5-Year Dividend Growth -100.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/12/25
Next Earnings Date 02/20/26 [--]
Earnings Per Share ttm -0.05
EPS Growth vs. Prev Qtr 0.00%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Most Recent Dividend 0.240 on 09/30/19
Next Ex-Dividends Date 09/30/19
Dividend Payable Date 10/15/19
Dividend Payout Ratio 0.00%

ENZN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -263.18%
Return-on-Assets % -6.49%
Profit Margin % 2,600.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow 6.68
Price/Book N/A
Book Value/Share 0.58
Interest Coverage -1.84
60-Month Beta 0.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar